Xilio Therapeutics, Inc. (XLO) investor relations documents from the company's IR site: 1 presentation, 25 press releases; latest deck 2026-08-12. Read in-app with summaries. First-party data.
Corporate Investor Presentation: Xilio's immuno-oncology platform uses masking technology to enable tumor-selective therapies with reduced side effects. Cash runway extends to Q1 2028.
XLO overview · XLO earnings · XLO financials · XLO KPIs · XLO ownership · XLO peers · XLO filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.